newsfilter
← Latest News
Business Wire·

Emmaus Life Sciences Reports Quarterly Financial Results

  • Emmaus Life Sciences reported financial results for the three and nine months ended September 30, 2026.
  • Net revenues for the three months ended September 30, 2026, were $1.9 million, a 44% decrease from $3.4 million in the same 2025 period.
  • The revenue decline was primarily driven by the May 15, 2026, effective date of a licensing agreement with NeoImmuneTech Inc. (NIT) that transferred direct sales of Endari®.
  • Management noted that the Middle East conflict also adversely affected net revenues in that region.
  • Total operating expenses for the three months were $1.9 million, down from $2.4 million in 2025, due to reduced costs from transferring the sales force to NIT.
  • The company reported a loss from operations of $0.4 million for the three months, compared to an income of $0.7 million in 2025.
  • Other expenses increased to $4.4 million for the three months from $2.2 million in 2025, mainly due to a change in the fair value of conversion features derivatives based on stock price increases.
  • Net loss for the three months was $4.7 million, or $0.07 per share, compared to a net loss of $2.1 million, or $0.03 per share, in 2025.
  • Cash \& cash equivalents stood at $1.0 million as of September 30, 2026, down from $2.1 million at December 31, 2025.
  • Endari® remains approved for marketing in the U.S., Israel, \& several Middle Eastern nations, with applications pending in Saudi Arabia \& early access in select European countries.
  • The company faces significant liabilities totaling $86.4 million as of September 30, 2026, against stockholders' deficit of $68.7 million.
Keywords
Biotechnology,Health,Pharmaceutical